The Open Group: Hybrid Big Data Technologies Developed From €4.5M European Union Research Project Enter Final Industrial Evaluations
15.12.2020 17:00:00 EET | Business Wire | Press release
The Open Group, the vendor-neutral technology consortium, and the University of York today announced a partnership with a consortium of leading European research organizations, software developers, and industrial big data users. Together, they will make hybrid big data accessible and easy to integrate within new applications and services through developing and evolving next generation technologies.
With support from the European Union, the Polyglot and Hybrid Persistence Architectures for Big Data Analytics (TYPHON) project has already invested €4.5 million (US$5.3 million) into advanced technology development. This funding has enabled the rapid creation of applications that bridge the many formats and architectures used to store data today. The integrated platform is currently undergoing first deployments within major organizations across the Telecom, Banking, Automotive, and Aerospace industries, and is being made widely available in open source format. By implementing the new technologies, organizations are able to enhance the productivity of their data architects, reduce development time and costs, and deliver new applications and services that make full use of existing big data stores.
Today’s development teams face substantial challenges when it comes to ensuring hybrid big data applications and services are designed coherently, which requires capturing a range of different formats that data is held within. To overcome these complexities, the TYPHON project has built a set of tools for developing, querying, evolving, analyzing, and monitoring hybrid big data polystores. These polystores readily combine numerous types of underlying storage technologies, including relational, graph-based, document-based, natural language, and big data islands.
David Lounsbury, Chief Digital Officer, The Open Group said: “The TYPHON project has brought together a range of industry experts who have collaborated to streamline the time intensive process of implementing intricate big data solutions. By connecting many different storage formats, the new technologies enable developers to deliver applications capable of effectively utilizing big data assets within organizations. The Open Group has a long-standing history of working with the University of York on complex systems. Together, we can provide the expertise and guidance needed to drive these technologies through final industrial evaluations.”
The advanced tools provide big data systems developers with:
- Technologies for designing hybrid polystores, taking into account the structure of the data, the availability, partitioning, and consistency requirements of different subsets of the data, and the available deployment resources
- Novel algorithms for transforming hybrid polystore design models into preconfigured optimized virtual machines which can be deployed on cloud infrastructure
- An extensible high-level language for querying and modifying data stored in hybrid polystores, as well as capabilities for translating high-level queries into efficient native queries
- A high-performance framework for publishing and processing data access and updating events to facilitate real-time monitoring and predictive analytics
- Technologies for evolving the organization and distribution of data in hybrid polystores, along with tools for monitoring use of polystores for enhanced evolution
Coordinated by The Open Group with technical leadership from the University of York, which has directed the advanced research, the TYPHON consortium includes:
- Centrum Wiskunde & Informatica, Edge Hill University, University of L’Aquila, University of Namur: recognized leaders in their respective fields of data query languages, natural language processing, data modelling languages, and hybrid data evolution
- CLMS and SWAT Engineering: leading providers of tools and services for big data applications development
- ATB: a research institute specializing in big data deployment technologies
- Alpha Bank, GMV, OTE, and Volkswagen: industry leaders in their respective sectors - Banking, Aerospace, Telecom, and Automotive – that are undertaking final evaluations of TYPHON project technologies within their big data applications
“With the availability of the TYPHON Modelling Language, Query Language, Deployment Language, and tools for creating, monitoring, and evolving new hybrid big data polystores, software developers can now rapidly create next generation applications and systems,” said Professor Dimitris Kolovos, University of York. “Through addressing key industry challenges, the TYPHON project is dedicated to ensuring hybrid big data solutions are designed, assembled, and configured consistently - ultimately enabling organizations to unlock the power of data.”
The technological advances and innovations resulting from the TYPHON project, as well as the final versions of the technologies in open source format are publically available via the project website: www.typhon-project.org
The TYPHON project receives funding under the European Union Horizon 2020 Research and Innovation Programme, an initiative of the European Community created to foster European research and the development of new technologies, applications, and industries.
-ENDS-
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org.
About the University of York
The Department of Computer Science at the University of York prepares graduates for the workplace at all levels through close collaboration with industry. The majority of the research work carried out has been classed as world-leading or internationally excellent and is focused around seven themes which align our academic strengths to best meet the greater scientific, social and environmental challenges of our time. Research teams work across disciplines within academia and industry with a strong focus placed on transforming research results into tangible solutions for industry. Further information on the University of York can be found at www.cs.york.ac.uk.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005656/en/
Contact information
Media Contact:
Jenny Morris
Hotwire PR (on behalf of The Open Group)
+44 (0)7393465529
UKOpengroup@hotwirepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
